Amélie Lusque

4.4k total citations
61 papers, 929 citations indexed

About

Amélie Lusque is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Amélie Lusque has authored 61 papers receiving a total of 929 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 27 papers in Pulmonary and Respiratory Medicine and 15 papers in Cancer Research. Recurrent topics in Amélie Lusque's work include Cancer Immunotherapy and Biomarkers (11 papers), Advanced Breast Cancer Therapies (10 papers) and Breast Cancer Treatment Studies (8 papers). Amélie Lusque is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Advanced Breast Cancer Therapies (10 papers) and Breast Cancer Treatment Studies (8 papers). Amélie Lusque collaborates with scholars based in France, Japan and United States. Amélie Lusque's co-authors include Julien Mazières, Thomas Filleron, Isabelle Rouquette, Anne Pradines, Gilles Favre, Nicolas Guibert, Jean Mourlanette, Nadia Boubekeur, Myriam Delaunay and Élodie Chantalat and has published in prestigious journals such as Nature Communications, Blood and Cancer Research.

In The Last Decade

Amélie Lusque

56 papers receiving 927 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amélie Lusque France 16 528 287 210 190 129 61 929
Andrea Fontana Italy 19 549 1.0× 335 1.2× 238 1.1× 285 1.5× 74 0.6× 50 1.0k
Dongqin Zhu China 18 308 0.6× 227 0.8× 152 0.7× 274 1.4× 107 0.8× 57 850
Elizabeth Crowley United States 16 473 0.9× 242 0.8× 112 0.5× 255 1.3× 244 1.9× 39 1.0k
Zachary A. Kohutek United States 11 494 0.9× 386 1.3× 358 1.7× 433 2.3× 107 0.8× 24 1.1k
Robert N. Raju United States 16 667 1.3× 241 0.8× 178 0.8× 284 1.5× 181 1.4× 30 985
John B. Hamner United States 13 331 0.6× 169 0.6× 227 1.1× 367 1.9× 84 0.7× 27 849
Annique M. Duyverman United States 8 593 1.1× 193 0.7× 348 1.7× 391 2.1× 78 0.6× 8 1.1k
Jorge Chaves United States 16 909 1.7× 365 1.3× 147 0.7× 211 1.1× 161 1.2× 41 1.2k
C.C. Engels Netherlands 16 341 0.6× 206 0.7× 190 0.9× 188 1.0× 40 0.3× 31 893
Chiara Lambertini Switzerland 15 607 1.1× 174 0.6× 148 0.7× 250 1.3× 202 1.6× 26 862

Countries citing papers authored by Amélie Lusque

Since Specialization
Citations

This map shows the geographic impact of Amélie Lusque's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amélie Lusque with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amélie Lusque more than expected).

Fields of papers citing papers by Amélie Lusque

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amélie Lusque. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amélie Lusque. The network helps show where Amélie Lusque may publish in the future.

Co-authorship network of co-authors of Amélie Lusque

This figure shows the co-authorship network connecting the top 25 collaborators of Amélie Lusque. A scholar is included among the top collaborators of Amélie Lusque based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amélie Lusque. Amélie Lusque is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lusque, Amélie, Stéphanie Brayer, Thomas Filleron, et al.. (2025). TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study. International Journal of Cancer. 157(3). 534–548.
2.
Lusque, Amélie, et al.. (2024). Radiation dose reduction during venous access port implantation: the importance of upgrading equipment and radiation-protection training. Irish Journal of Medical Science (1971 -). 193(3). 1461–1466. 1 indexed citations
3.
Lusque, Amélie, Véronique Dièras, Élise Deluche, et al.. (2024). 343MO Unraveling the mechanisms of action and resistance to trastuzumab deruxtecan (T-DXd): Supplementary biomarker analyses from DAISY trial. Annals of Oncology. 35. S359–S359. 2 indexed citations
4.
Epaillard, Nicolas, Amélie Lusque, William Jacot, et al.. (2024). Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort. ESMO Open. 9(5). 103447–103447. 3 indexed citations
5.
Suc, Bertrand, E. Cohen-Jonathan Moyal, Jean‐Marie Péron, et al.. (2024). Stereotactic body radiation therapy in primary liver tumor: Local control, outcomes and toxicities. Clinical and Translational Radiation Oncology. 50. 100892–100892. 1 indexed citations
6.
Alapetite, Claire, Stéphanie Bolle, F. Goudjil, et al.. (2024). Brainstem toxicity after proton or photon therapy in children and young adults with localized intracranial ependymoma: A French retrospective study. Radiotherapy and Oncology. 194. 110157–110157. 5 indexed citations
7.
Chaltiel, Léonor, Carole Massabeau, Audrey Rabeau, et al.. (2023). Impact of radiation on host immune system in patients treated with chemoradiotherapy and durvalumab consolidation for unresectable locally advanced non-small cell lung cancer. Frontiers in Oncology. 13. 1186479–1186479. 8 indexed citations
8.
Frenel, Jean‐Sébastien, Amélie Lusque, Suzette Delaloge, et al.. (2023). Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation. British Journal of Cancer. 128(11). 2072–2080. 3 indexed citations
9.
Lusque, Amélie, Véronique Dièras, Élise Deluche, et al.. (2022). LBA72 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial. Annals of Oncology. 33. S1440–S1440. 12 indexed citations
10.
11.
Montfort, Anne, Thomas Filleron, Cécile Pagès, et al.. (2020). Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial. Clinical Cancer Research. 27(4). 1037–1047. 70 indexed citations
12.
Gangloff, D., et al.. (2020). Axillary node dissection in outpatient procedure, is it feasible and safe?. Journal of Gynecology Obstetrics and Human Reproduction. 50(5). 101931–101931. 1 indexed citations
13.
Leray, Hélène, Amélie Lusque, Élodie Chantalat, et al.. (2020). Body Mass Index as a Major Risk Factor for Severe Breast Cancer-Related Lymphedema. Lymphatic Research and Biology. 18(6). 510–516. 37 indexed citations
14.
Mazieres, J., Pascale Tomasini, Amélie Lusque, et al.. (2020). 1279P Impact of KRAS mutations and subtypes on efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC). Annals of Oncology. 31. S826–S827. 10 indexed citations
15.
16.
Morvan, Valérie Le, Élodie Richard, Delphine Fessart, et al.. (2020). Cytochrome P450 1B1 polymorphism drives cancer cell stemness and patient outcome in head-and-neck carcinoma. British Journal of Cancer. 123(5). 772–784. 12 indexed citations
17.
Bergoglio, Valérie, Yea‐Lih Lin, Marie‐Jeanne Pillaire, et al.. (2019). Overexpression of Claspin and Timeless protects cancer cells from replication stress in a checkpoint-independent manner. Nature Communications. 10(1). 910–910. 96 indexed citations
18.
Guellec, Sophie Le, Amélie Lusque, Élodie Chantalat, et al.. (2019). Breast desmoid tumor management in France: toward a new strategy. Breast Cancer Research and Treatment. 176(2). 329–335. 30 indexed citations
19.
Mosele, M.F., Amélie Lusque, Alicia Tran Dien, et al.. (2019). Outcome and mutational landscape of patients with PIK3CA-mutated metastatic breast cancer (mBC). Annals of Oncology. 30. iii47–iii47. 4 indexed citations
20.
Lusque, Amélie, et al.. (2019). Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients. La Presse Médicale. 48(4). e199–e207. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrea Fontana Breakdown of academic impact, for papers by Dongqin Zhu Breakdown of academic impact, for papers by Elizabeth Crowley Breakdown of academic impact, for papers by Zachary A. Kohutek Breakdown of academic impact, for papers by Robert N. Raju Breakdown of academic impact, for papers by John B. Hamner Breakdown of academic impact, for papers by Annique M. Duyverman Breakdown of academic impact, for papers by Jorge Chaves Breakdown of academic impact, for papers by C.C. Engels Breakdown of academic impact, for papers by Chiara Lambertini
Rankless by CCL
2026